Evidence map›Paper›PMID 30937601›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer.

Meagan S Whisenant, Faith A Strunk, Debasish Tripathy, Loretta A Williams

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Meagan S WhisenantDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX, 77030, USA. mswhisenant@mdanderson.org.ORCID http://orcid.org/0000-0002-9791-1227
Faith A StrunkDepartment of Acute and Continuing Care, The University of Texas Health Science Center at Houston School of Nursing, 6901 Bertner Avenue, SON-686, Houston, TX, 77030, USA.
Debasish TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX, 77030, USA.
Loretta A WilliamsDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX, 77030, USA.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

Hawn Foundation Fund for Education Programs in Pain and Symptom Research Postdoctoral FellowshipOncology Nursing Society Houston Chapter Research Project GrantZeta Pi Chapter of Sigma Theta Tau International Honor Society of Nursing Research Project Grant
6 · The paper itself

Abstract

purposeThe American Cancer Society predicted that 266,120 women would be diagnosed with breast cancer in 2018. Women experience significant symptom burden in response to tumor and treatment-related adverse effects, particularly in advanced disease. Use of valid and reliable patient-reported outcomes (PRO) symptom measures may assist clinicians in systematically monitoring and managing symptoms. The MD Anderson Symptom Inventory (MDASI) is a brief PRO measure of cancer symptom burden; specific symptoms can be added to the core symptoms to produce disease- and treatment-specific modules. The purpose of this study was to describe the patient symptom experience, define the content domain, and generate items for a breast cancer-specific MDASI module for measuring symptom burden in women with breast cancer.

methodsWomen with breast cancer were qualitatively interviewed about their experiences of disease and treatment. Descriptive exploratory analysis identified symptoms and symptom interference to define the symptom burden of breast cancer. An expert panel rated the relevance of the identified symptoms to patients with breast cancer.

resultsA conceptual model of breast cancer symptom burden was developed from interviews with 36 women (mean age of 57.9 years, 86.1% had stages I-III, and 52.8% were on chemotherapy and/or radiation therapy) across the breast cancer disease and treatment trajectory. Thirty-six symptoms and 6 interference categories were identified. Symptoms specific to treatment modalities and breast cancer met the criteria for inclusion in the provisional instrument for psychometric testing.

conclusionsWe generated an instrument with content validity for measuring symptom burden specific to women with breast cancer.

Indexed as

Breast NeoplasmsFemaleHumansMiddle AgedNeoplasm StagingPatient Reported Outcome MeasuresPsychometricsReproducibility of ResultsSeverity of Illness IndexSickness Impact ProfileTumor BurdenBreast cancerChemotherapyEndocrine therapyHormonal therapyOncologyPatient-reported outcomesSymptoms

Identifiers

PMID30937601
OpenAlexW2926607817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.